{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:33:14Z","timestamp":1793093594450,"version":"4.5.0"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T00:00:00Z","timestamp":1643068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The aim of this study was to investigate association of autoantibodies with scleroderma renal crisis (SRC) among Japanese patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The clinical characteristics and mortality of 330 patients with sytemic screlosis (SSc) at Kyoto University Hospital were retrospectively analysed, focusing on possible association with anti-topoisomerase I (anti-topo I), anti-centromere (ACA), anti-RNA polymerase III (RNAPIII) and\/or anti-U1-RNP. Logistic regression analyses were performed to reveal any association of these autoantibodies with the development and mortality of SRC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>SRC was observed in 24 out of 330 SSc patients, including patients with anti-topo I (n\u2009=\u200912\/24, 50%), anti-RNAPIII (n\u2009=\u20097\/24, 29%), anti-U1-RNP (n\u2009=\u20095\/24, 21%) and ACA (n\u2009=\u20093\/24, 13%). Anti-U1-RNP [odds ratio (95% CI), 3.63 (1.11, 10.2)], anti-topo I [3.22 (1.37, 7.57)] and anti-RNAPIII (3.29 [1.16, 8.70]) were associated with the development of SRC. Furthermore, anti-topo I [6.00 (1.11, 41.1)] was associated with 1-year mortality of SRC. The 1-year survival rate after the onset of SRC among all patients and among those positive for anti-topo I was 54% and 33%, respectively. In contrast, the survival rate in patients negative for anti-topo I was 75%, of which the survival rate of patients positive for anti-RNAPIII and ACA was 83% and 100%, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Specific SSc-related autoantibodies were associated with the morbidity and mortality of SRC.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keac047","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T20:12:54Z","timestamp":1643055174000},"page":"4130-4135","source":"Crossref","is-referenced-by-count":15,"title":["Autoantibody profiles associated with morbidity and mortality in scleroderma renal crisis"],"prefix":"10.1093","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2521-246X","authenticated-orcid":false,"given":"Hideaki","family":"Tsuji","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine , Kyoto"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuo","family":"Kuramoto","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Wakayama Medical University , Wakayama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuneo","family":"Sasai","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine , Kyoto"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirei","family":"Shirakashi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine , Kyoto"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Onizawa","sequence":"additional","affiliation":[{"name":"Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine , Kyoto"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji\u00a0","family":"Kitagori","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine , Kyoto"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Akizuki","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine , Kyoto"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Nakashima","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine , Kyoto"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryu","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine , Kyoto"},{"name":"Department of Clinical Immunology, Osaka City University Graduate School of Medicine , Osaka"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Onishi","sequence":"additional","affiliation":[{"name":"Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine , Kyoto"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5981-4648","authenticated-orcid":false,"given":"Kosaku","family":"Murakami","sequence":"additional","affiliation":[{"name":"Division of Clinical Immunology and Cancer Immunotherapy, Center for Cancer Immunotherapy and Immunobiology, Kyoto University Graduate School of Medicine , Kyoto"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Yoshifuji","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine , Kyoto"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine , Kyoto"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motomu","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine , Kyoto"},{"name":"Department of Clinical Immunology, Osaka City University Graduate School of Medicine , Osaka"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Ohmura","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Kobe City Medical Center General Hospital , Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Morinobu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine , Kyoto"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,1,25]]},"reference":[{"key":"2022100812084812100_keac047-B1","doi-asserted-by":"crossref","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"2022100812084812100_keac047-B2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3899\/jrheum.180582","article-title":"Scleroderma renal crisis: risk factors for an increasingly rare organ complication","volume":"47","author":"Moinzadeh","year":"2020","journal-title":"J Rheumatol"},{"key":"2022100812084812100_keac047-B3","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/art.41153","article-title":"Using autoantibodies and cutaneous subset to develop outcome-based disease classification in systemic sclerosis","volume":"72","author":"Nihtyanova","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2022100812084812100_keac047-B4","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/art.38994","article-title":"Clinical and immunologic predictors of scleroderma renal crisis in Japanese systemic sclerosis patients with anti-RNA polymerase III autoantibodies","volume":"67","author":"Hamaguchi","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2022100812084812100_keac047-B5","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s12016-009-8191-5","article-title":"Scleroderma renal crisis: a rare but severe complication of systemic sclerosis","volume":"40","author":"Mouthon","year":"2011","journal-title":"Clin Rev Allergy Immunol"},{"key":"2022100812084812100_keac047-B6","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/art.30111","article-title":"HLA-DRB1*0407 and *1304 are risk factors for scleroderma renal crisis","volume":"63","author":"Nguyen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2022100812084812100_keac047-B7","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.3899\/jrheum.080806","article-title":"Serologic profile and mortality rates of scleroderma renal crisis in Italy","volume":"36","author":"Codullo","year":"2009","journal-title":"J Rheumatol"},{"key":"2022100812084812100_keac047-B8","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1620\/tjem.239.297","article-title":"High prevalence of acute exacerbation of interstitial lung disease in Japanese patients with systemic sclerosis","volume":"239","author":"Tomiyama","year":"2016","journal-title":"Tohoku J Exp Med"},{"key":"2022100812084812100_keac047-B9","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1346-8138.2009.00762.x","article-title":"Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis","volume":"37","author":"Hamaguchi","year":"2010","journal-title":"J Dermatol"},{"key":"2022100812084812100_keac047-B10","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/art.1780230510","article-title":"Preliminary criteria for the classification of systemic sclerosis (scleroderma)","volume":"23","author":"Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee","year":"1980","journal-title":"Arthritis Rheum"},{"key":"2022100812084812100_keac047-B11","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2022100812084812100_keac047-B12","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.semarthrit.2013.09.008","article-title":"Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis\u2014results from the International Scleroderma Renal Crisis Survey","volume":"43","author":"Hudson","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"2022100812084812100_keac047-B13","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/rheumatology\/kep375","article-title":"The RIG-I\u2013like receptor IFIH1\/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody","volume":"49","author":"Nakashima","year":"2010","journal-title":"Rheumatology (Oxford)"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keac047\/42503117\/keac047.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/10\/4130\/46383027\/keac047.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/10\/4130\/46383027\/keac047.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T12:10:55Z","timestamp":1665231055000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/10\/4130\/6515269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,25]]},"references-count":13,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,1,25]]},"published-print":{"date-parts":[[2022,10,6]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keac047","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,10,1]]},"published":{"date-parts":[[2022,1,25]]}}}